Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.

Saved in:
Bibliographic Details
Title: Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
Authors: Stupp, R.1, Tosoni, A.2, Bromberg, J. E. C.3, Hau, P.4, Campone, M.5, Gijtenbeek, J.6, Frenay, M.7, Breimer, L.8, Wiesinger, H.9, Allgeier, A.10, van den Bent, M. J.3, Bogdahn, U.4, van der Graaf, W.6, Yun, H. J.10, Gorlia, T.10, Lacombe, D.10, Brandes, A. A.2
Source: Annals of Oncology. Sep2011, Vol. 22 Issue 9, p2144-2149. 6p. 1 Diagram, 3 Charts, 2 Graphs.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdq729